Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 9, 2019updated 24 Dec 2019 7:10am

Ipsen places hold on paediatric patients in palovarotene’s studies

Ipsen has placed a partial clinical hold on all global sites of the Phase II PVO-1A-202/204, PVO-2A-201, and Phase III PVO-1A-301 clinical trials assessing palovarotene.

Ipsen has placed a partial clinical hold on all global sites of the Phase II PVO-1A-202/204, PVO-2A-201, and Phase III PVO-1A-301 clinical trials assessing palovarotene.

The clinical hold is for paediatric patients aged below 14 years and comes after discussions with the US Food and Drug Administration (FDA).

Palovarotene is an investigational retinoic acid receptor gamma (RARγ) agonist. Ipsen added the drug to its portfolio with the acquisition of Clementia Pharmaceuticals.

In these Phase II and Phase III trials, the drug is being assessed for the chronic treatment of fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).

The clinical hold was placed after safety reports revealed early growth plate closure in paediatric FOP patients treated with the drug. Ipsen recently submitted the reports to the FDA.

This hold is contingent on a pending review of further information about the serious adverse events. The US regulator intends to request additional details within the coming 30 days.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

While no such events were observed in the MO data reported to date, the study has also been put on hold because the events were associated with chronic dosing in the FOP programme.

The MO study mainly consists of paediatric patients, leading to a temporary halt of treatment for all participants, along with further enrolment.

The company said in a statement: “Ipsen is committed to researching and developing therapies for children and adults living with FOP and MO, two rare and devastating bone diseases with no current therapeutic treatment options.

“Ipsen is committed to working diligently with the FDA to provide all requested information with the goal of resolving the partial clinical hold.”

The company is currently working to submit a new drug application (NDA) to the FDA for palovarotene in acute/flare-up FOP.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU